Table 1.
Baseline clinical characteristics.
| Characteristics | ERA + riociguat + selexipag (n = 37) | ERA + PDE5i + selexipag (n = 155) | p Value |
|---|---|---|---|
| Age, years | 43.8 ± 11.9 | 42.8 ± 15.4 | .711 |
| Female, n (%) | 29 (78.4) | 119 (76.8) | .835 |
| BMI, | 23.7 ± 4.0 | 22.4 ± 4.4 | .306 |
| HR, bpm | 86.8 ± 12.7 | 81.6 ± 18.6 | .122 |
| RR, bpm | 20.1 ± 1.5 | 19.7 ± 1.8 | .265 |
| SBP, mmHg | 108.3 ± 12.2 | 112.8 ± 14.8 | .099 |
| DBP, mmHg | 66.4 ± 9.9 | 69.1 ± 12.8 | .248 |
| Classification | .362 | ||
| IPAH, n (%) | 23 (62.2) | 74 (47.7) | |
| CHD‐PAH, n (%) | 6 (16.2) | 40 (25.8) | |
| CTD‐PAH, n (%) | 8 (21.6) | 38 (24.5) | |
| HHT, n (%) | 0 (0) | 3 (1.9) | |
| WHO FC II/III/IV, n | 6/24/7 | 34/102/19 | .484 |
| 6MWD, m | 271.8 ± 173.4 | 313.4 ± 146.9 | .210 |
| NT‐proBNP, pg/mL | 2041(1218–3870) | 1445 (475–3016) | .126 |
| Risk stratifications, n (%) | |||
| 1/2/3/4a | 4/2/17/14 | 18/33/74/30 | .035 |
| Event, n (%) | 6 (16.2) | 17 (11.0) | .440 |
| Adverse event,b n (%) | 16 (43.2) | 66 (42.6) | .963 |
| Hemodynamics characteristics | |||
| mRAP, mmHg | 12.5 ± 11.7 | 7.4 ± 6.0 | .120 |
| mPAP, mmHg | 72.0 ± 10.8 | 62.0 ± 17.2 | .112 |
| mPAWP, mmHg | 13.5 ± 6.5 | 9.3 ± 3.8 | .072 |
| CO, L/min | 4.3 ± 1.6 | 4.2 ± 1.3 | .766 |
| CI, L/min/m2 | 2.5 ± 0.7 | 2.5 + 0.8 | .965 |
| PVR, WU | 13.4 ± 7.2 | 13.9 ± 6.8 | .817 |
| TPR, WU | 14.9 ± 10.7 | 11.6 ± 8.9 | .426 |
| SVO2, % | 58.2 ± 4.8 | 61.5 ± 11.2 | .391 |
Note: Data are presented as n (%), mean ± standard deviation, and interquartile range.
Abbreviations: 6MWD, 6‐minute walking distance; BMI, body mass index; CHD‐PAH, congenital heart disease‐associated pulmonary arterial hypertension; CI, cardiac index; CO, cardiac output; CTD‐PAH, connective tissue disease‐associated pulmonary arterial hypertension; DBP, diastolic blood pressure; ERA, endothelin receptor antagonist; HHT, hereditary hemorrhagic telangiectasia; HR, heart rate; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; mPAWP, mean pulmonary arterial wedge pressure; mRAP, mean right atrial pressure; NT‐proBNP, N‐terminal probrain natriuretic peptide; PDE5i, phosphodiesterase 5 inhibitor; PVR, pulmonary vascular resistance; RR, respiratory rate; SBP, systolic blood pressure; SVO2, mixed venous oxygen saturation; TPR, total pulmonary resistance; WHO FC, World Health Organization functional class; WU, wood units.
1/2/3/4, low/intermediate‐low//intermediate‐high/high risk.
Means the 6 months‐long‐term adverse event not the short‐term adverse effect after taking medication.